201 related articles for article (PubMed ID: 37071962)
1. Bifunctional degraders of cyclin dependent kinase 9 (CDK9): Probing the relationship between linker length, properties, and selective protein degradation.
Tokarski RJ; Sharpe CM; Huntsman AC; Mize BK; Ayinde OR; Stahl EH; Lerma JR; Reed A; Carmichael B; Muthusamy N; Byrd JC; Fuchs JR
Eur J Med Chem; 2023 Jun; 254():115342. PubMed ID: 37071962
[TBL] [Abstract][Full Text] [Related]
2. Discovery of selective CDK9 degraders with enhancing antiproliferative activity through PROTAC conversion.
Qiu X; Li Y; Yu B; Ren J; Huang H; Wang M; Ding H; Li Z; Wang J; Bian J
Eur J Med Chem; 2021 Feb; 211():113091. PubMed ID: 33338869
[TBL] [Abstract][Full Text] [Related]
3. Development of Human Carbonic Anhydrase II Heterobifunctional Degraders.
O'Herin CB; Moriuchi YW; Bemis TA; Kohlbrand AJ; Burkart MD; Cohen SM
J Med Chem; 2023 Feb; 66(4):2789-2803. PubMed ID: 36735827
[TBL] [Abstract][Full Text] [Related]
4. Functional Genomics Identify Distinct and Overlapping Genes Mediating Resistance to Different Classes of Heterobifunctional Degraders of Oncoproteins.
Shirasaki R; Matthews GM; Gandolfi S; de Matos Simoes R; Buckley DL; Raja Vora J; Sievers QL; Brüggenthies JB; Dashevsky O; Poarch H; Tang H; Bariteau MA; Sheffer M; Hu Y; Downey-Kopyscinski SL; Hengeveld PJ; Glassner BJ; Dhimolea E; Ott CJ; Zhang T; Kwiatkowski NP; Laubach JP; Schlossman RL; Richardson PG; Culhane AC; Groen RWJ; Fischer ES; Vazquez F; Tsherniak A; Hahn WC; Levy J; Auclair D; Licht JD; Keats JJ; Boise LH; Ebert BL; Bradner JE; Gray NS; Mitsiades CS
Cell Rep; 2021 Jan; 34(1):108532. PubMed ID: 33406420
[TBL] [Abstract][Full Text] [Related]
5. Discovery of Wogonin-based PROTACs against CDK9 and capable of achieving antitumor activity.
Bian J; Ren J; Li Y; Wang J; Xu X; Feng Y; Tang H; Wang Y; Li Z
Bioorg Chem; 2018 Dec; 81():373-381. PubMed ID: 30196207
[TBL] [Abstract][Full Text] [Related]
6. Modulation of FLT3-ITD and CDK9 in acute myeloid leukaemia cells by novel proteolysis targeting chimera (PROTAC).
Řezníčková E; Krajčovičová S; Peřina M; Kovalová M; Soural M; Kryštof V
Eur J Med Chem; 2022 Dec; 243():114792. PubMed ID: 36191408
[TBL] [Abstract][Full Text] [Related]
7. PROTACs: Current Trends in Protein Degradation by Proteolysis-Targeting Chimeras.
Madan J; Ahuja VK; Dua K; Samajdar S; Ramchandra M; Giri S
BioDrugs; 2022 Sep; 36(5):609-623. PubMed ID: 36098871
[TBL] [Abstract][Full Text] [Related]
8. Small molecule PROTACs in targeted therapy: An emerging strategy to induce protein degradation.
Xi M; Chen Y; Yang H; Xu H; Du K; Wu C; Xu Y; Deng L; Luo X; Yu L; Wu Y; Gao X; Cai T; Chen B; Shen R; Sun H
Eur J Med Chem; 2019 Jul; 174():159-180. PubMed ID: 31035238
[TBL] [Abstract][Full Text] [Related]
9. New Frontiers in the Discovery and Development of PROTACs.
Barghout SH
Anticancer Agents Med Chem; 2022 Aug; 22(15):2656-2661. PubMed ID: 35418290
[TBL] [Abstract][Full Text] [Related]
10. Combinatorial Ubiquitination REal-time PROteolysis (CURE-PROs): A Modular Platform for Generating Reversible, Self-Assembling Bifunctional Targeted Degraders.
Giardina SF; Valdambrini E; Singh PK; Bacolod MD; Babu-Karunakaran G; Peel M; Warren JD; Barany F
J Med Chem; 2024 Apr; 67(7):5473-5501. PubMed ID: 38554135
[TBL] [Abstract][Full Text] [Related]
11. Modeling the CRL4A ligase complex to predict target protein ubiquitination induced by cereblon-recruiting PROTACs.
Bai N; Riching KM; Makaju A; Wu H; Acker TM; Ou SC; Zhang Y; Shen X; Bulloch DN; Rui H; Gibson BW; Daniels DL; Urh M; Rock BM; Humphreys SC
J Biol Chem; 2022 Apr; 298(4):101653. PubMed ID: 35101445
[TBL] [Abstract][Full Text] [Related]
12. Proteolysis-targeting chimeras for targeting protein for degradation.
Qi J; Zhang G
Future Med Chem; 2019 Apr; 11(7):723-741. PubMed ID: 30706727
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological perturbation of CDK9 using selective CDK9 inhibition or degradation.
Olson CM; Jiang B; Erb MA; Liang Y; Doctor ZM; Zhang Z; Zhang T; Kwiatkowski N; Boukhali M; Green JL; Haas W; Nomanbhoy T; Fischer ES; Young RA; Bradner JE; Winter GE; Gray NS
Nat Chem Biol; 2018 Feb; 14(2):163-170. PubMed ID: 29251720
[TBL] [Abstract][Full Text] [Related]
14. The importance of cellular degradation kinetics for understanding mechanisms in targeted protein degradation.
Riching KM; Caine EA; Urh M; Daniels DL
Chem Soc Rev; 2022 Jul; 51(14):6210-6221. PubMed ID: 35792307
[TBL] [Abstract][Full Text] [Related]
15. Advancing targeted protein degradation for cancer therapy.
Dale B; Cheng M; Park KS; Kaniskan HÜ; Xiong Y; Jin J
Nat Rev Cancer; 2021 Oct; 21(10):638-654. PubMed ID: 34131295
[TBL] [Abstract][Full Text] [Related]
16. E3 ligase ligand chemistries: from building blocks to protein degraders.
Sosič I; Bricelj A; Steinebach C
Chem Soc Rev; 2022 May; 51(9):3487-3534. PubMed ID: 35393989
[TBL] [Abstract][Full Text] [Related]
17. Chemically induced degradation of epigenetic targets.
Kabir M; Yu X; Kaniskan HÜ; Jin J
Chem Soc Rev; 2023 Jul; 52(13):4313-4342. PubMed ID: 37314393
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and biological evaluation of a tumor-selective degrader of PARP1.
Pu C; Wang S; Luo D; Liu Y; Ma X; Zhang H; Yu S; Lan S; Huang Q; Deng R; He X; Li R
Bioorg Med Chem; 2022 Sep; 69():116908. PubMed ID: 35780655
[TBL] [Abstract][Full Text] [Related]
19. Design, Synthesis and Biological Evaluation of α-Synuclein Proteolysis-Targeting Chimeras.
Wen T; Chen J; Zhang W; Pang J
Molecules; 2023 May; 28(11):. PubMed ID: 37298935
[TBL] [Abstract][Full Text] [Related]
20. Recent Developments in the Biology and Medicinal Chemistry of CDK9 Inhibitors: An Update.
Wu T; Qin Z; Tian Y; Wang J; Xu C; Li Z; Bian J
J Med Chem; 2020 Nov; 63(22):13228-13257. PubMed ID: 32866383
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
